Literature DB >> 33361098

Longitudinal course of clinical lung clearance index in children with cystic fibrosis.

Bettina S Frauchiger1, Severin Binggeli1, Sophie Yammine1, Ben Spycher2, Linn Krüger1, Kathryn A Ramsey1,3, Philipp Latzin1,3.   

Abstract

BACKGROUND: Although the lung clearance index (LCI) is a sensitive marker of small airway disease in individuals with cystic fibrosis (CF), less is known about longitudinal changes in LCI during routine clinical surveillance. Here, our objectives were to describe the longitudinal course of LCI in children with CF during routine clinical surveillance and assess influencing factors.
METHODS: Children with CF aged 3-18 years performed LCI measurements every 3 months as part of routine clinical care between 2011 and 2018. We recorded clinical data at every visit. We used a multilevel mixed effect model to determine changes in LCI over time and identify clinical factors that influence LCI course.
RESULTS: We collected LCI measurements from 1204 visits (3603 trials) in 78 participants, of which 907 visits had acceptable LCI data. The average unadjusted increase in LCI for the entire population was 0.29 (95% CI 0.20-0.38) LCI units·year-1. The increase in LCI was more pronounced in adolescence (0.41 (95% CI 0.27-0.54) LCI units·year-1). Colonisation with either Pseudomonas aeruginosa or Aspergillus fumigatus, pulmonary exacerbations, CF-related diabetes and bronchopulmonary aspergillosis were associated with a higher increase in LCI over time. Adjusting for clinical risk factors reduced the increase in LCI over time to 0.24 (95% CI 0.16-0.33) LCI units·year-1.
CONCLUSIONS: LCI measured during routine clinical surveillance is associated with underlying disease progression in children with CF. An increased change in LCI over time should prompt further diagnostic intervention.
Copyright ©ERS 2021. For reproduction rights and permissions contact permissions@ersnet.org.

Entities:  

Year:  2021        PMID: 33361098     DOI: 10.1183/13993003.02686-2020

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  11 in total

Review 1.  Progress and challenges in fungal lung disease in cystic fibrosis.

Authors:  Gina Hong
Journal:  Curr Opin Pulm Med       Date:  2022-09-19       Impact factor: 2.868

2.  Clinical Impact of Aspergillus fumigatus in Children with Cystic Fibrosis.

Authors:  Valentina Fainardi; Chiara Sodini; Michela Deolmi; Andrea Ciuni; Kaltra Skenderaj; Maria Bice Stabile; Cosimo Neglia; Elena Mariotti Zani; Cinzia Spaggiari; Nicola Sverzellati; Susanna Esposito; Giovanna Pisi
Journal:  Microorganisms       Date:  2022-03-29

Review 3.  ERS International Congress 2021: highlights from the Paediatric Assembly.

Authors:  Cristina Ardura-Garcia; Alicia Abellan; Sara Cuevas-Ocaña; Nadine Freitag; Yin Ting Lam; Heidi Makrinioti; Monique Slaats; Matteo Storti; Emma E Williams; Theodore Dassios; Liesbeth Duijts; Refika H Ersu; Stojka Fustik; Rory E Morty; Marijke Proesmans; Dirk Schramm; Sejal Saglani; Alexander Moeller; Marielle W Pijnenburg
Journal:  ERJ Open Res       Date:  2022-05-23

4.  School-age structural and functional MRI and lung function in children following lung resection for congenital lung malformation in infancy.

Authors:  Corin Willers; Lukas Maager; Grzegorz Bauman; Dietmar Cholewa; Enno Stranzinger; Luigi Raio; Carmen Casaulta; Philipp Latzin
Journal:  Pediatr Radiol       Date:  2022-03-19

5.  Novel volumetric capnography indices measure ventilation inhomogeneity in cystic fibrosis.

Authors:  Sotirios Fouzas; Anne-Christianne Kentgens; Olga Lagiou; Bettina Sarah Frauchiger; Florian Wyler; Ilias Theodorakopoulos; Sophie Yammine; Philipp Latzin
Journal:  ERJ Open Res       Date:  2022-03-14

6.  Lung clearance index to characterize clinical phenotypes of children and adolescents with cystic fibrosis.

Authors:  Simone Gambazza; Federico Ambrogi; Federica Carta; Laura Moroni; Maria Russo; Anna Brivio; Carla Colombo
Journal:  BMC Pulm Med       Date:  2022-04-01       Impact factor: 3.317

7.  Do clinimetric properties of LCI change after correction of signal processing?

Authors:  Bettina S Frauchiger; Marc-Alexander Oestreich; Florian Wyler; Nathalie Monney; Corin Willers; Sophie Yammine; Philipp Latzin
Journal:  Pediatr Pulmonol       Date:  2022-03-09

8.  A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele.

Authors:  Edith T Zemanick; Jennifer L Taylor-Cousar; Jane Davies; Ronald L Gibson; Marcus A Mall; Edward F McKone; Paul McNally; Bonnie W Ramsey; Jonathan H Rayment; Steven M Rowe; Elizabeth Tullis; Neil Ahluwalia; Chenghao Chu; Thang Ho; Samuel M Moskowitz; Sabrina Noel; Simon Tian; David Waltz; Tanya G Weinstock; Fengjuan Xuan; Claire E Wainwright; Susanna A McColley
Journal:  Am J Respir Crit Care Med       Date:  2021-06-15       Impact factor: 21.405

9.  The Relation between Vitamin D Level and Lung Clearance Index in Cystic Fibrosis-A Pilot Study.

Authors:  Mihaela Dediu; Ioana Mihaiela Ciuca; Liviu Laurentiu Pop; Daniela Iacob
Journal:  Children (Basel)       Date:  2022-03-01

10.  Longitudinal assessment of lung clearance index to monitor disease progression in children and adults with cystic fibrosis.

Authors:  Alex R Horsley; John Belcher; Katie Bayfield; Brooke Bianco; Steve Cunningham; Catherine Fullwood; Andrew Jones; Anna Shawcross; Jaclyn A Smith; Anirban Maitra; Francis J Gilchrist
Journal:  Thorax       Date:  2021-07-22       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.